News

The company’s latest report states that this growth, which will occur across the 10 major markets of the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and

Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on: advancing its APD334 program, including the ongoing Phase 2 clinical trial for

According to IMS, for the 12 months ending August 2015, the US market for Chlorothiazide approximated $29m. As with all products in Sagent’s portfolio, Chlorothiazide features Sagent’s PreventIV

The company said a review of data from a phase III trial of losmapimod for heart treatment did not indicate efficacy against the primary endpoint. Losmapimod was being

Trek Therapeutics recently secured an exclusive worldwide license from Theravance Biopharma to develop, manufacture, use, market and sell TD-6450 as a component in combination HCV products. Under the

The study, funded by the Medical Research Council and Alzheimer’s Society, involved 295 people who had been diagnosed with moderate to severe Alzheimer’s disease. The main objective of

In the expansion phase of the trial, 448 patients were given an oral formulation of the omecamtiv mecarbil drug for 20 weeks and observed for 24 weeks. Patients

The 33,000 square foot facility provides 25 percent more space than PRA’s previous lab, includes investments in the newest small and large molecule equipment, and allows for optimal

The company said patients taking the FDA-approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking